

Immunic says preclinical data for vidofludimus calcium is a milestone for its lead MS program



NEWS RELEASE BY IMMUNIC INC

London, UK | May 17, 2023 10:00 AM Eastern Daylight Time



Immunic Inc president and CEO Dr Daniel Vitt joined Proactive's Stephen Gunnion with news of the publication of preclinical data confirming that vidofludimus calcium (IMU-838) acts as a potent nuclear receptor-related 1 (Nurr1) activator, in addition to its known mode of action as a dihydroorotate dehydrogenase (DHODH) inhibitor.

Vitt said described it as another exciting milestone for Immunic's lead development program as it suggests that Nurr1 may be responsible for the drug's postulated neuroprotective effects. The company has also taken steps to strengthen its intellectual property position with the submission of a new patent application in the United States and European Union, he added.

Contact Details

Proactive United States

+1 347-449-0879

action@proactiveinvestors.com

Tags

HEALTH

BIOTECH

PHARMA

MS

PARKINSONS